Skip to main content
Article thumbnail
Location of Repository

Question 26. What is the natural history of the disorder?



Question 26: What is the natural history of the disorder? Question 27: What is the impact of a positive (or negative) test on patient care? Question 28: If applicable, are diagnostic tests available? Question 29: Is there an effective remedy or acceptable action, or other measurable benefit? Question 30: Is there general access to that remedy or action? Question 31: Is the test being offered to a socially vulnerable population? Question 32: What quality assurance measures are in place? Question 33: What are the results of pilot trials? Question 34: What health risks can be identified for follow-up testing and/or intervention. Question 35: What are the financial costs associated with testing? Question 36: What are the economic benefits associated with actions resulting from testing? Question 37: What facilities/personnel are available or easily put in place? Question 38: What educational materials have been developed and validated, and which of these are available? Question 39: Are there informed consent requirements? Question 40: What methods exist for long term monitoring? Question 41: What guidelines have been developed for evaluating program performance? BRCA and Breast/Ovarian Cancer-- Clinical Utility Version 2004-3 4-1CLINICAL UTILIT

Year: 2011
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.